Fatty acid treatment
CA 2070468 A1 · Owner: Efamol Holdings Plc · Inventors: Horrobin, David Frederick; Buck, Alfred Colin
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Reduction of urinary calcium excretion in humans or animals by the administration of GLA or DGLA as much or in salt or other pharmacologically acceptable form optionally in association with EPA, DHA or other EFA in similar forms is also, useful in the treatment of nephrocalcinosis renal stones and osteoporosis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 4, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 4, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 4, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.